Neuropharmacological assessment of growth hormone secretion.

Neuropharmacological assessment of growth hormone secretion. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Neuropharmacological assessment of growth hormone secretion. Abstract Text:

The biochemical diagnosis of individuals who are either deficient in growth hormone (GH) or who have alterations in the normal pattern of GH secretion is difficult. The uncertainty surrounding diagnosis reflects the lack of a thorough understanding of the physiology of GH secretion and of the hypothalamic hormones involved. At least three hormones are implicated: GH-releasing hormone (GHRH), somatostatin and the endogenous ligand of the GH secretagogue receptor, although the role that each plays in the release of GH is not clear from the available experimental evidence. In such a situation, most of the dynamic tests of GH secretory capacity in humans need to undergo a 'trial and error' process before being validated. The search for the 'gold standard' test of GH secretion is ongoing, and the combination of GHRH plus GH secretagogues will probably play an important role in future clinical diagnosis.

Neuropharmacological assessment of growth hormone secretion. Publishing Authors By Initials

For similar hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pituitary hormone release inhibiting hormones: somatostatin research abstracts see: hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pituitary hormone release inhibiting hormones: somatostatin research

PUBMED ID PMID:

MEDLINE DATE:

Neuropharmacological assessment of growth hormone secretion. Journal Published:

PUBLICATION TYPE: Review

Journal: Acta paediatrica (Oslo, Norway : 1992). Supplement

VOLUME: 423

Page Numbers: 12-6

Journal Abbreviation: Acta Paediatr Suppl

ISSN: 0803-5326

DAY: 12

MONTH: Nov

YEAR: 1997

Neuropharmacological assessment of growth hormone secretion. Information

Number of References: 32

LANGUAGE: eng

NlmUniqueID: 9315043

Neuropharmacological assessment of growth hormone secretion. Keywords Mesh Terms:

KEYWORDS: Somatostatin

MESH TERMS: physiology

Chemical & Substance for Abstract: Neuropharmacological assessment of growth hormone secretion. Information

Substance Name: Growth Hormone-Releasing Hormone

Registry Number: 9034-39-3

Grant and Affiliation Information for Neuropharmacological assessment of growth hormone secretion.

AFFILIATION: Department of Physiology, Complejo Hospitalario de Santiago, Santiago de Compostela University, Spain.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Paediatr Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Neuropharmacological assessment of growth hormone secretion Related Publications

• Combined growth hormone-releasing hormone and growth hormone-releasing peptide-6 test for the evaluation of growth hormone secretion in children with growth hormone deficiency and growth hormone neurosecretory dysfunction.
• Ghrelin and the enteroinsular axis in healthy men.
• Ghrelin: from a GH-secretagogue to the regulation of food intake, sleep and anxiety.
• Growth hormone and somatostatin directly inhibit gastric ghrelin secretion. An in vitro organ culture system.
• Growth hormone secretagogues in pathological states: diagnostic implications.
• Influence of metabolic substrates and obesity on growth hormone secretion.
• Leptin, nutrition and reproduction: new insights.
• Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line - role of mitogenic activated protein kinase signaling pathway.
• Neuropharmacological assessment of growth hormone secretion.
• Pituitary tumorigenesis.
• Risk for postpartum depression, breastfeeding practices, and mammary gland permeability.
• Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin.
• Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome.
• [Determining factors in the suspension of breast feeding in a group of urban population]